RNA splicing factor RBFOX2 is a key factor in the progression of cancer and cardiomyopathy

IF 7.9 1区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Clinical and Translational Medicine Pub Date : 2024-09-07 DOI:10.1002/ctm2.1788

Jinze Shen, Jianqiao Shentu, Chenming Zhong, Qiankai Huang, Shiwei Duan

{"title":"RNA splicing factor RBFOX2 is a key factor in the progression of cancer and cardiomyopathy","authors":"Jinze Shen, Jianqiao Shentu, Chenming Zhong, Qiankai Huang, Shiwei Duan","doi":"10.1002/ctm2.1788","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Alternative splicing of pre-mRNA is a fundamental regulatory process in multicellular eukaryotes, significantly contributing to the diversification of the human proteome. RNA-binding fox-1 homologue 2 (RBFOX2), a member of the evolutionarily conserved RBFOX family, has emerged as a critical splicing regulator, playing a pivotal role in the alternative splicing of pre-mRNA. This review provides a comprehensive analysis of RBFOX2, elucidating its splicing activity through direct and indirect binding mechanisms. RBFOX2 exerts substantial influence over the alternative splicing of numerous transcripts, thereby shaping essential cellular processes such as differentiation and development.</p>\n </section>\n \n <section>\n \n <h3> Main body of the abstract</h3>\n \n <p>Dysregulation of RBFOX2-mediated alternative splicing has been closely linked to a spectrum of cardiovascular diseases and malignant tumours, underscoring its potential as a therapeutic target. Despite significant progress, current research faces notable challenges. The complete structural characterisation of RBFOX2 remains elusive, limiting in-depth exploration beyond its RNA-recognition motif. Furthermore, the scarcity of studies focusing on RBFOX2-targeting drugs poses a hindrance to translating research findings into clinical applications.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This review critically assesses the existing body of knowledge on RBFOX2, highlighting research gaps and limitations. By delineating these areas, this analysis not only serves as a foundational reference for future studies but also provides strategic insights for bridging these gaps. Addressing these challenges will be instrumental in unlocking the full therapeutic potential of RBFOX2, paving the way for innovative and effective treatments in various diseases.</p>\n </section>\n </div>","PeriodicalId":10189,"journal":{"name":"Clinical and Translational Medicine","volume":null,"pages":null},"PeriodicalIF":7.9000,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctm2.1788","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ctm2.1788","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Alternative splicing of pre-mRNA is a fundamental regulatory process in multicellular eukaryotes, significantly contributing to the diversification of the human proteome. RNA-binding fox-1 homologue 2 (RBFOX2), a member of the evolutionarily conserved RBFOX family, has emerged as a critical splicing regulator, playing a pivotal role in the alternative splicing of pre-mRNA. This review provides a comprehensive analysis of RBFOX2, elucidating its splicing activity through direct and indirect binding mechanisms. RBFOX2 exerts substantial influence over the alternative splicing of numerous transcripts, thereby shaping essential cellular processes such as differentiation and development.

Main body of the abstract

Dysregulation of RBFOX2-mediated alternative splicing has been closely linked to a spectrum of cardiovascular diseases and malignant tumours, underscoring its potential as a therapeutic target. Despite significant progress, current research faces notable challenges. The complete structural characterisation of RBFOX2 remains elusive, limiting in-depth exploration beyond its RNA-recognition motif. Furthermore, the scarcity of studies focusing on RBFOX2-targeting drugs poses a hindrance to translating research findings into clinical applications.

Conclusion

This review critically assesses the existing body of knowledge on RBFOX2, highlighting research gaps and limitations. By delineating these areas, this analysis not only serves as a foundational reference for future studies but also provides strategic insights for bridging these gaps. Addressing these challenges will be instrumental in unlocking the full therapeutic potential of RBFOX2, paving the way for innovative and effective treatments in various diseases.

Abstract Image

查看原文本刊更多论文

RNA 剪接因子 RBFOX2 是癌症和心肌病进展的关键因素。

背景：前mRNA的交替剪接是多细胞真核生物的一个基本调控过程，对人类蛋白质组的多样化做出了重要贡献。RNA 结合狐-1 同源物 2（RBFOX2）是进化保守的 RBFOX 家族的成员，它已成为一个关键的剪接调节因子，在前 mRNA 的交替剪接中发挥着关键作用。本综述对 RBFOX2 进行了全面分析，通过直接和间接的结合机制阐明了它的剪接活性。摘要正文：RBFOX2 介导的替代剪接失调与一系列心血管疾病和恶性肿瘤密切相关，凸显了其作为治疗靶点的潜力。尽管取得了重大进展，但目前的研究仍面临着明显的挑战。RBFOX2 的完整结构特征仍然难以确定，限制了对其 RNA 识别基团以外的深入研究。此外，针对 RBFOX2 靶向药物的研究很少，阻碍了将研究成果转化为临床应用：本综述批判性地评估了有关 RBFOX2 的现有知识体系，强调了研究空白和局限性。通过对这些领域的划分，本分析报告不仅为未来研究提供了基础参考，还为弥补这些差距提供了战略性见解。应对这些挑战将有助于释放 RBFOX2 的全部治疗潜力，为各种疾病的创新和有效治疗铺平道路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Translational Medicine Multiple-

CiteScore

15.90

自引率

1.90%

发文量

450

审稿时长

4 weeks

期刊介绍： Clinical and Translational Medicine (CTM) is an international, peer-reviewed, open-access journal dedicated to accelerating the translation of preclinical research into clinical applications and fostering communication between basic and clinical scientists. It highlights the clinical potential and application of various fields including biotechnologies, biomaterials, bioengineering, biomarkers, molecular medicine, omics science, bioinformatics, immunology, molecular imaging, drug discovery, regulation, and health policy. With a focus on the bench-to-bedside approach, CTM prioritizes studies and clinical observations that generate hypotheses relevant to patients and diseases, guiding investigations in cellular and molecular medicine. The journal encourages submissions from clinicians, researchers, policymakers, and industry professionals.

文献相关原料

公司名称	产品信息	采购帮参考价格